Literature DB >> 8819215

Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.

C Orskov1, A Wettergren, J J Holst.   

Abstract

BACKGROUND: The insulinotropic hormones gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), secreted from the K-cells of the upper small intestine and from the L-cells of the lower small intestine, respectively, are thought to be responsible for intestinal stimulation of insulin secretion. If true, their plasma concentrations should parallel the meal-related diurnal changes in plasma insulin concentrations.
METHODS: Using COOH-terminal assays, thought to reflect accurately their rates of secretion, we measured circulating levels of GIP and GLP-1 in six normal subjects for 15 h of a day, during which they ate three mixed meals.
RESULTS: Both GIP and GLP-1 concentrations increased significantly and in parallel with insulin in response to all three meals. The plasma insulin concentrations correlated significantly with both GIP and GLP-1 values throughout the study period (correlation coefficients, 0.49 +/- 0.07 and 0.56 +/- 0.05; p < 0.001).
CONCLUSIONS: These results support the notion that GLP-1 and GIP are important incretin hormones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8819215     DOI: 10.3109/00365529609009147

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  56 in total

Review 1.  Bariatric surgery evolution from the malabsorptive to the hormonal era.

Authors:  Ehab Akkary
Journal:  Obes Surg       Date:  2012-05       Impact factor: 4.129

2.  cAMP-independent effects of GLP-1 on β cells.

Authors:  Jelena Kolic; Patrick E MacDonald
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

Review 3.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 4.  Intestinal GLP-1 and satiation: from man to rodents and back.

Authors:  R E Steinert; C Beglinger; W Langhans
Journal:  Int J Obes (Lond)       Date:  2015-08-28       Impact factor: 5.095

5.  The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.

Authors:  A Wettergren; M Wøjdemann; S Meisner; F Stadil; J J Holst
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

6.  Inhibition of human gastric lipase secretion by glucagon-like peptide-1.

Authors:  M Wøjdemann; A Wettergren; B Sternby; J J Holst; S Larsen; J F Rehfeld; O Olsen
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

7.  Contributions of fat and protein to the incretin effect of a mixed meal.

Authors:  Guillaume Carrel; Léonie Egli; Christel Tran; Philippe Schneiter; Vittorio Giusti; David D'Alessio; Luc Tappy
Journal:  Am J Clin Nutr       Date:  2011-08-17       Impact factor: 7.045

8.  An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.

Authors:  Mary Jane Geiger; Zachary Skrivanek; Brenda Gaydos; Jenny Chien; Scott Berry; Donald Berry
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

9.  Mechanisms behind the superior effects of interval vs continuous training on glycaemic control in individuals with type 2 diabetes: a randomised controlled trial.

Authors:  Kristian Karstoft; Kamilla Winding; Sine H Knudsen; Noemi G James; Maria M Scheel; Jesper Olesen; Jens J Holst; Bente K Pedersen; Thomas P J Solomon
Journal:  Diabetologia       Date:  2014-08-07       Impact factor: 10.122

Review 10.  The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.

Authors:  James Crane; Barbara McGowan
Journal:  Ther Adv Chronic Dis       Date:  2015-12-16       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.